Inside: unterbewertete Biochtechperle bricht aus! - 500 Beiträge pro Seite
eröffnet am 30.11.04 18:23:29 von
neuester Beitrag 10.01.05 13:55:54 von
neuester Beitrag 10.01.05 13:55:54 von
Beiträge: 18
ID: 931.192
ID: 931.192
Aufrufe heute: 0
Gesamt: 1.480
Gesamt: 1.480
Aktive User: 0
ISIN: US43738R1095 · WKN: A0B6PY
Werte aus der Branche Banken
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 25,80 | +27,69 | |
| 10,675 | +27,54 | |
| 2,5300 | +24,63 | |
| 124,06 | +24,36 | |
| 1,9000 | +22,46 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,4224 | -9,94 | |
| 6,4035 | -11,04 | |
| 22,200 | -17,78 | |
| 13,370 | -18,77 | |
| 2,6800 | -37,09 |
Feedback
NASDAQ : HMSL
News? Mein Tip: 1,5$ auf 1 Monat
Bald über 1$, unterbewertete Biochtechperle bricht aus!
HOMEPAGE:
http://www.hemosol.com/index.cfm
1 Monat
1 Jahr
das sieht gut aus!!!!
Realtime Java Orderbuch (HMSL eingeben):
http://datasvr.tradearca.com/arcadataserver/JArcaBook.php
Ich würde mir ein paar Stücke in Depot legen! Hab gesehen Ihr kauft in Deutschland? Da ist kein Handel, Ihr bezahlt viel zu viel. Habe selber an der Nasdaq geordert. Da ist viel Handel!!!
News? Mein Tip: 1,5$ auf 1 Monat
Bald über 1$, unterbewertete Biochtechperle bricht aus!
HOMEPAGE:
http://www.hemosol.com/index.cfm
1 Monat
1 Jahr
das sieht gut aus!!!!Realtime Java Orderbuch (HMSL eingeben):
http://datasvr.tradearca.com/arcadataserver/JArcaBook.php
Ich würde mir ein paar Stücke in Depot legen! Hab gesehen Ihr kauft in Deutschland? Da ist kein Handel, Ihr bezahlt viel zu viel. Habe selber an der Nasdaq geordert. Da ist viel Handel!!!
Ich empfehle diese Stücke für jedes Depot!!! Soviiel Käufe sind nicht normal, schaut Euch den Umsatz sonst an, ich denke da wissen Insider mehr.
Hemosol is a biopharmaceutical company focused on the development and manufacturing of biologics, particularly blood-related proteins. The Company has a broad range of novel therapeutic products in development, including HEMOLINK [hemoglobin raffimer], an oxygen therapeutic designed to rapidly and safely improve oxygen delivery via the circulatory system. Hemosol also is developing additional oxygen therapeutics, a hemoglobin-based drug delivery platform to treat diseases such as hepatitis C and cancers of the liver, and a cell therapy program initially directed to the treatment of cancer. Hemosol intends to leverage its expertise in manufacturing blood proteins and its state-of-the-art Meadowpine manufacturing facility to seek additional strategic growth opportunities.
About HEMOLINK
HEMOLINK is a life sustaining therapeutic, designed to deliver oxygen immediately, effectively and safely to the body`s tissues and organs. HEMOLINK is a leader in an emerging new class of drugs that reflect a new approach to the treatment of patients suffering from acute anemia.
Building a Robust Pipeline
Hemosol`s expertise in the bioconjugation of proteins is also being used in the development of its own late-discovery phase drug delivery products directed at anti-viral and anti-cancer therapeutics. The Company`s cell expansion technology includes a process to expand hemoglobin-producing cells, which could eventually lead to a raw-material source for HEMOLINK and a process to expand therapeutic gamma delta T cells for the treatment of patients with Chronic Myelogenous Leukemia, already approved for a Phase I clinical trial in Canada. Several other promising projects in the discovery phase of development round out the Company`s products in development.
Hemosol is a biopharmaceutical company focused on the development and manufacturing of biologics, particularly blood-related proteins. The Company has a broad range of novel therapeutic products in development, including HEMOLINK [hemoglobin raffimer], an oxygen therapeutic designed to rapidly and safely improve oxygen delivery via the circulatory system. Hemosol also is developing additional oxygen therapeutics, a hemoglobin-based drug delivery platform to treat diseases such as hepatitis C and cancers of the liver, and a cell therapy program initially directed to the treatment of cancer. Hemosol intends to leverage its expertise in manufacturing blood proteins and its state-of-the-art Meadowpine manufacturing facility to seek additional strategic growth opportunities.
About HEMOLINK
HEMOLINK is a life sustaining therapeutic, designed to deliver oxygen immediately, effectively and safely to the body`s tissues and organs. HEMOLINK is a leader in an emerging new class of drugs that reflect a new approach to the treatment of patients suffering from acute anemia.
Building a Robust Pipeline
Hemosol`s expertise in the bioconjugation of proteins is also being used in the development of its own late-discovery phase drug delivery products directed at anti-viral and anti-cancer therapeutics. The Company`s cell expansion technology includes a process to expand hemoglobin-producing cells, which could eventually lead to a raw-material source for HEMOLINK and a process to expand therapeutic gamma delta T cells for the treatment of patients with Chronic Myelogenous Leukemia, already approved for a Phase I clinical trial in Canada. Several other promising projects in the discovery phase of development round out the Company`s products in development.
PRNewswire-FirstCall via COMTEX/ -- Hemosol (HMSL) today announced that it has signed a multi-year agreement with Organon Canada, the pharmaceutical division of Akzo Nobel. This agreement, with an initial term of three years, will see Hemosol become the exclusive Canadian manufacturer and supplier of licensed "Hepalean(R)" products to Organon.
Shipments of the first Hepalean products are scheduled to begin in early 2005 subsequent to the completion of manufacturing process validation and licensing of the Meadowpine facility. Revenue from this agreement is expected to contribute to reducing Hemosol`s burn rate beginning in 2005.
"This agreement represents a major step in our strategy to leverage our state-of-the-art Meadowpine facility and bio-manufacturing expertise to produce high value biopharmaceutical products and more specifically validates our experience and capability in the area of protein manufacturing," said Dr. Dirk Alkema, Vice President, Operations of Hemosol. "We will also be acquiring a much needed capability in terms of vial fill/finish that rounds out our portfolio as we move forward with our other commitments including our previously announced strategic alliance with ProMetic and the American Red Cross."
Hemosol`s addition of a vial filling line to fulfil this agreement complements Hemosol`s existing capability of aseptic filling into IV transfusion bags. The new capacity will also support other business opportunities that Hemosol is pursuing.
Organon`s Hepalean products are derived from heparin sodium, an agent used in the treatment of thrombophlebitis, phlebothrombosis, and cerebral, coronary, and retinal vessel thrombosis to prevent extension of clots and thromboembolic phenomena. Heparin is also used prophylactically to prevent the occurrence of thromboembolism, and to prevent clotting during dialysis and other surgical procedures, particularly vascular surgery. Hepalean is the only line of heparin that offers presentations that are preservative free.
"Our decision to contract with Hemosol was based on their key competencies and experience," said Fred Hendriksen, President, of Organon Canada. "Built to extract, purify and manufacture proteins, Hemosol`s world- class Meadowpine manufacturing facility and related capabilities are perfectly suited to manufacture our Hepalean products and we anticipate other opportunities between Organon and Hemosol."
About Organon Canada
Organon is the largest of the three pharmaceutical business units of Akzo Nobel, a leading global company in health care products, coatings and chemicals. Headquartered in The Netherlands, Akzo Nobel currently employs 67,900 people in 80 countries. Its sales totalled Euro 14 billion in 2002. Organon is a global leader in the creation of innovative prescription medicines for gynaecology, mental health, anaesthesia, and cardiovascular disease - products that contribute to the health of people and their quality of life.
Organon, headquartered in Roseland, NJ, USA creates and markets prescription medicines that improve the health and quality of human life. Through a combination of independent growth and business partnerships, Organon strives to become or remain one of the leading pharmaceutical companies in each of its core therapeutic fields: reproductive medicine, psychiatry and anaesthesia. Organon products are sold in over 100 countries, of which more than 60 have an Organon subsidiary. Organon is the human health care business unit of Akzo Nobel.
Organon Canada Ltd., located in Toronto, sells Puregon, Marvelon, Remeron RD, Zemuron, and Andriol. For more information visit Organon Canada`s website at www.organon.ca
About Hemosol
Hemosol is a biopharmaceutical company focused on the development and manufacturing of biologics, particularly blood-related proteins. Hemosol is leveraging its expertise in manufacturing blood proteins and its state-of-the- art Meadowpine manufacturing facility to seek additional strategic growth opportunities. Hemosol has a broad range of novel therapeutic products in development, including HEMOLINK(TM) (hemoglobin raffimer), oxygen therapeutic designed to rapidly and safely improve oxygen delivery via the circulatory system. Hemosol is also developing next generation oxygen therapeutics, a hemoglobin-based drug delivery platform to treat diseases such as hepatitis C and liver cancers, and a cell therapy program initially directed to the treatment of cancer.
For more information visit Hemosol`s website at www.hemosol.com.
Hemosol`s common shares are listed on the NASDAQ Stock Market under the trading symbol "HMSL" and on the Toronto Stock Exchange under the trading symbol "HML".
Certain statements concerning Hemosol`s future prospects are "forward- looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and other applicable securities legislation. There can be no assurances that future results will be achieved, and actual results could differ materially from forecasts and estimates. Important factors that could cause actual results to differ materially from forecasts and estimates include, but are not limited to: Hemosol`s ability to obtain regulatory approvals for its products; Hemosol`s ability to successfully complete clinical trials for its products and enter into satisfactory arrangements for the supply of materials used in its manufacturing operations and the sale of resulting products to customers; technical, manufacturing or distribution issues; the competitive environment for Hemosol`s products; the degree of market penetration of Hemosol`s products; Hemosol`s ability to obtain sufficient financing to complete clinical development of its products; and other factors set forth in filings with Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission. These risks and uncertainties, as well as others, are discussed in greater detail in the filings of Hemosol with Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission. Hemosol makes no commitment to revise or update any forward-looking statements in order to reflect events or circumstances after the date any such statement is made.
SOURCE Hemosol Corp.
Shipments of the first Hepalean products are scheduled to begin in early 2005 subsequent to the completion of manufacturing process validation and licensing of the Meadowpine facility. Revenue from this agreement is expected to contribute to reducing Hemosol`s burn rate beginning in 2005.
"This agreement represents a major step in our strategy to leverage our state-of-the-art Meadowpine facility and bio-manufacturing expertise to produce high value biopharmaceutical products and more specifically validates our experience and capability in the area of protein manufacturing," said Dr. Dirk Alkema, Vice President, Operations of Hemosol. "We will also be acquiring a much needed capability in terms of vial fill/finish that rounds out our portfolio as we move forward with our other commitments including our previously announced strategic alliance with ProMetic and the American Red Cross."
Hemosol`s addition of a vial filling line to fulfil this agreement complements Hemosol`s existing capability of aseptic filling into IV transfusion bags. The new capacity will also support other business opportunities that Hemosol is pursuing.
Organon`s Hepalean products are derived from heparin sodium, an agent used in the treatment of thrombophlebitis, phlebothrombosis, and cerebral, coronary, and retinal vessel thrombosis to prevent extension of clots and thromboembolic phenomena. Heparin is also used prophylactically to prevent the occurrence of thromboembolism, and to prevent clotting during dialysis and other surgical procedures, particularly vascular surgery. Hepalean is the only line of heparin that offers presentations that are preservative free.
"Our decision to contract with Hemosol was based on their key competencies and experience," said Fred Hendriksen, President, of Organon Canada. "Built to extract, purify and manufacture proteins, Hemosol`s world- class Meadowpine manufacturing facility and related capabilities are perfectly suited to manufacture our Hepalean products and we anticipate other opportunities between Organon and Hemosol."
About Organon Canada
Organon is the largest of the three pharmaceutical business units of Akzo Nobel, a leading global company in health care products, coatings and chemicals. Headquartered in The Netherlands, Akzo Nobel currently employs 67,900 people in 80 countries. Its sales totalled Euro 14 billion in 2002. Organon is a global leader in the creation of innovative prescription medicines for gynaecology, mental health, anaesthesia, and cardiovascular disease - products that contribute to the health of people and their quality of life.
Organon, headquartered in Roseland, NJ, USA creates and markets prescription medicines that improve the health and quality of human life. Through a combination of independent growth and business partnerships, Organon strives to become or remain one of the leading pharmaceutical companies in each of its core therapeutic fields: reproductive medicine, psychiatry and anaesthesia. Organon products are sold in over 100 countries, of which more than 60 have an Organon subsidiary. Organon is the human health care business unit of Akzo Nobel.
Organon Canada Ltd., located in Toronto, sells Puregon, Marvelon, Remeron RD, Zemuron, and Andriol. For more information visit Organon Canada`s website at www.organon.ca
About Hemosol
Hemosol is a biopharmaceutical company focused on the development and manufacturing of biologics, particularly blood-related proteins. Hemosol is leveraging its expertise in manufacturing blood proteins and its state-of-the- art Meadowpine manufacturing facility to seek additional strategic growth opportunities. Hemosol has a broad range of novel therapeutic products in development, including HEMOLINK(TM) (hemoglobin raffimer), oxygen therapeutic designed to rapidly and safely improve oxygen delivery via the circulatory system. Hemosol is also developing next generation oxygen therapeutics, a hemoglobin-based drug delivery platform to treat diseases such as hepatitis C and liver cancers, and a cell therapy program initially directed to the treatment of cancer.
For more information visit Hemosol`s website at www.hemosol.com.
Hemosol`s common shares are listed on the NASDAQ Stock Market under the trading symbol "HMSL" and on the Toronto Stock Exchange under the trading symbol "HML".
Certain statements concerning Hemosol`s future prospects are "forward- looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and other applicable securities legislation. There can be no assurances that future results will be achieved, and actual results could differ materially from forecasts and estimates. Important factors that could cause actual results to differ materially from forecasts and estimates include, but are not limited to: Hemosol`s ability to obtain regulatory approvals for its products; Hemosol`s ability to successfully complete clinical trials for its products and enter into satisfactory arrangements for the supply of materials used in its manufacturing operations and the sale of resulting products to customers; technical, manufacturing or distribution issues; the competitive environment for Hemosol`s products; the degree of market penetration of Hemosol`s products; Hemosol`s ability to obtain sufficient financing to complete clinical development of its products; and other factors set forth in filings with Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission. These risks and uncertainties, as well as others, are discussed in greater detail in the filings of Hemosol with Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission. Hemosol makes no commitment to revise or update any forward-looking statements in order to reflect events or circumstances after the date any such statement is made.
SOURCE Hemosol Corp.
Chancen Risiko Verhältniss ist sehr gut!!
Auf zu neuen Höhen!!!!!!!!!!
Auf zu neuen Höhen!!!!!!!!!!
Wenn eine Biotech-Aktie unterbewertet ist, dann IMCLONE ! Die Firma macht seit der Zulassung im Sommer Mega-Gewinne mit Erbitux und der Aktienkurs hat sich seitdem
halbiert ! Wie dämlich ist die Menschheit eigentlich? Statt dessen wird so ein Mist wie Morphosys gekauft, deutsche Biotechnologie, also 3.Liga !
Trading Spotlight
Ich finde IMCL sehr gut, hatte sie schon mehrmals, allerdings brechen mir die Großen Biotechs in letzter Zeit zu oft ein. Ich denke die Zeiten mit IMCL viel Geld zu verdienen sind rum. Man muss kleine Unternehmen finden die ein ähnliches Potential haben.
Ich bin mir HMSL sehr sicher, das die Aktie das Potential hat kurzfristig über 1,5$ zu springen, auch ohne News! Der Chart ist super.
Strong Buy!
Strong Buy!
ebenfalls gut investiert Ihr in HOFF, ich bin sicher HOFF bricht in den nächsten 2 Tagen aus!!!
NASDAQ: HOFF
Realtime Orderbuch
http://data.inetats.com/ds/data/stockstats/stockstats.jsp?wi…
NASDAQ: HOFF
Realtime Orderbuch
http://data.inetats.com/ds/data/stockstats/stockstats.jsp?wi…
noch was positives zu HOFF:
http://data.inetats.com/ds/data/stockstats/stockstats.jsp?wi…
28 Käufer zu 25 Verkäufer
Heute Inraday Chance!!!
http://data.inetats.com/ds/data/stockstats/stockstats.jsp?wi…
28 Käufer zu 25 Verkäufer
Heute Inraday Chance!!!
HMSL schliesst heute mit 0,9$
morgen sehen wir die 1$
morgen sehen wir die 1$
wer in der letzten Zeit auf meine Empfehlungen gehört hat, der hat mächtig verdient. VRLK geht nun auf die 100%(von 1,8-3,00$ zu, SPAB (mal 100% dann wieder raus, dann wieder rein) auf die 2,5$ XEDA von 0,4 auf 0,7$ usw...
HOFF und HMSL bei diesen beiden gehts ebenfalls bald richtig los
HOFF und HMSL bei diesen beiden gehts ebenfalls bald richtig los
sehe gerade VRLK ist wieder dicke im Plus, danke Gott für meine Gabe sloche Aktien zu finden 
HMSL 13%
Hallo, habe noch eine gute Aktie entdeckt, wird auch bald richtig ausbrechen, werde morgen ein paar ordern.
Varian Medical Systems 852812
Varian Medical Systems 852812
18%
+ 22%
Kurs: 0,91
unter 1,4-1,6$ keine mehr hergeben!!!!!! Da ist was grösseres im Busch
Kurs: 0,91
unter 1,4-1,6$ keine mehr hergeben!!!!!! Da ist was grösseres im Busch
hi biom
1.arc deal steht an!
2.sind an der nasdaq geblieben!
3.die letzten nachrichten sind alle gut!
4.der chart (volumen) spricht seine eigene sprache!
5.halte das teil schon mehrere jahre...
...nun wirds zeit!...
gruß
xqc
1.arc deal steht an!
2.sind an der nasdaq geblieben!
3.die letzten nachrichten sind alle gut!
4.der chart (volumen) spricht seine eigene sprache!
5.halte das teil schon mehrere jahre...
...nun wirds zeit!...
gruß
xqc
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 206 | ||
| 103 | ||
| 84 | ||
| 73 | ||
| 62 | ||
| 42 | ||
| 41 | ||
| 39 | ||
| 33 | ||
| 31 |
| Wertpapier | Beiträge | |
|---|---|---|
| 24 | ||
| 22 | ||
| 22 | ||
| 21 | ||
| 18 | ||
| 17 | ||
| 17 | ||
| 15 | ||
| 15 | ||
| 15 |
